Charles River Laboratories Intl. Inc (NYSE:CRL) Shares Sold by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. cut its holdings in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 2.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,170 shares of the medical research company’s stock after selling 84 shares during the period. Oppenheimer & Co. Inc.’s holdings in Charles River Laboratories Intl. were worth $450,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Flagship Harbor Advisors LLC grew its position in shares of Charles River Laboratories Intl. by 132.1% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 318 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 181 shares during the period. Steward Partners Investment Advisory LLC purchased a new stake in Charles River Laboratories Intl. during the second quarter valued at approximately $69,000. Machina Capital S.A.S. acquired a new stake in Charles River Laboratories Intl. in the second quarter valued at approximately $72,000. Hilton Capital Management LLC acquired a new stake in Charles River Laboratories Intl. in the first quarter valued at approximately $118,000. Finally, Cigna Investments Inc. New purchased a new position in Charles River Laboratories Intl. in the first quarter worth $201,000. Institutional investors own 94.40% of the company’s stock.

CRL stock traded up $1.26 during mid-day trading on Wednesday, reaching $130.94. 4,343 shares of the stock traded hands, compared to its average volume of 233,653. The company has a quick ratio of 1.38, a current ratio of 1.59 and a debt-to-equity ratio of 1.47. Charles River Laboratories Intl. Inc has a 52 week low of $103.00 and a 52 week high of $149.07. The business has a 50-day moving average of $132.09 and a two-hundred day moving average of $136.35. The firm has a market capitalization of $6.35 billion, a PE ratio of 21.62, a P/E/G ratio of 1.66 and a beta of 1.09.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Wednesday, July 31st. The medical research company reported $1.63 EPS for the quarter, topping analysts’ consensus estimates of $1.55 by $0.08. The business had revenue of $657.60 million for the quarter, compared to analyst estimates of $662.61 million. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.62 earnings per share. On average, equities research analysts anticipate that Charles River Laboratories Intl. Inc will post 6.52 EPS for the current fiscal year.

A number of equities analysts have recently issued reports on the company. Leerink Swann assumed coverage on Charles River Laboratories Intl. in a research report on Monday, June 10th. They set an “outperform” rating on the stock. ValuEngine downgraded Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Monday. Finally, Svb Leerink began coverage on Charles River Laboratories Intl. in a research note on Monday, June 10th. They issued an “outperform” rating and a $155.00 price objective on the stock. Seven equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $147.62.

In other news, insider David Ross Smith sold 1,249 shares of Charles River Laboratories Intl. stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $130.36, for a total transaction of $162,819.64. Following the completion of the sale, the insider now owns 19,327 shares in the company, valued at approximately $2,519,467.72. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.80% of the company’s stock.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: Quick Ratio

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.